Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,822 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,088 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04851119 | Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors | recruiting | Phase 1 / Phase 2 | 147 | Children's Oncology GroupNETWORK | 1 | Aug 25, 2026 | clinicaltrials |
| NCT06975293 | STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas | recruiting | Phase 1 / Phase 2 | 107 | STORM Therapeutics LTDINDUSTRY | 1 | Aug 25, 2026 |
| NCT07193511 | BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001) | recruiting | Phase 1 / Phase 2 | 355 | Avenzo Therapeutics, Inc.INDUSTRY | 1 | Aug 25, 2026 | clinicaltrials |
| NCT07594626 | BMS-986504 in Combination With Pemetrexed for the Treatment of Metastatic Solid Tumors With MTAP Deletion | recruiting | Phase 1 / Phase 2 | 72 | Northwestern UniversityOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT07785609 | A Clinical Trial of MK-2010 With Sacituzumab Tirumotecan (Sac-TMT) in Participants With Solid Tumors (MK-2010) | not yet recruiting | Phase 2 | 200 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 25, 2026 | clinicaltrials |
| NCT02992210 | Study on GD2 Positive Solid Tumors by 4SCAR-GD2 | not yet recruiting | Phase 1 / Phase 2 | 10 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT05554380 | Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With PTEN/AKT Mutations, A ComboMATCH Treatment Trial | active not recruiting | Phase 2 | 33 | National Cancer Institute (NCI)NIH | 2 | Aug 24, 2026 | clinicaltrials |
| NCT06417554 | A Trial of SHR-A2102 With or Without Antitumor Therapy in Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 80 | Shanghai Hengrui Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 24, 2026 | clinicaltrials |
| NCT04068194 | Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies | active not recruiting | Phase 1 / Phase 2 | 103 | National Cancer Institute (NCI)NIH | 1 | Aug 21, 2026 | clinicaltrials |
| NCT05554367 | Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial | active not recruiting | Phase 2 | 199 | National Cancer Institute (NCI)NIH | 2 | Aug 21, 2026 | clinicaltrials |
| NCT05593094 | A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 210 | Hoffmann-La RocheINDUSTRY | 7 | Aug 21, 2026 | clinicaltrials |
| NCT05701306 | APG-115 Alone or in Combination With APG-2575 in Recurrent or Refractory Neuroblastoma or Solid Tumors | recruiting | Phase 1 / Phase 2 | 100 | Ascentage Pharma Group Inc.INDUSTRY | 1 | Aug 21, 2026 | clinicaltrials |
| NCT06885281 | A Study of ZL-1310 in Participants With Selected Solid Tumors | recruiting | Phase 1 / Phase 2 | 166 | Zai Lab (Shanghai) Co., Ltd.INDUSTRY | 2 | Aug 21, 2026 | clinicaltrials |
| NCT05269381 | Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors(PNeoVCA) | recruiting | Phase 1 / Phase 2 | 138 | Mayo ClinicOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT06154291 | FIH XON7 in Advanced/Metastatic Solid Tumors(FIPO23) | recruiting | Phase 1 / Phase 2 | 255 | Xenothera SASINDUSTRY | 2 | Aug 20, 2026 | clinicaltrials |
| NCT06741644 | A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 800 | CStone PharmaceuticalsINDUSTRY | 3 | Aug 20, 2026 | clinicaltrials |
| NCT04104776 | A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas | recruiting | Phase 1 / Phase 2 | 300 | Novartis PharmaceuticalsINDUSTRY | 7 | Aug 19, 2026 | clinicaltrials |
| NCT04550494 | Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations | active not recruiting | Phase 2 | 29 | National Cancer Institute (NCI)NIH | 1 | Aug 19, 2026 | clinicaltrials |
| NCT04725474 | First-in-Human Study of the GDF-15 Neutralizing Antibody Visugromab (CTL-002) in Patients With Advanced Cancer (GDFATHER)(GDFATHER) | active not recruiting | Phase 1 / Phase 2 | 199 | CatalYm GmbHINDUSTRY | 3 | Aug 19, 2026 | clinicaltrials |
| NCT06144671 | Phase I/II Clinical Study of GT201 Injection as Monotherapy or in Combination With PD-1 Inhibitor for Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 78 | Grit BiotechnologyINDUSTRY | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07246863 | Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC | recruiting | Phase 2 | 131 | CatalYm GmbHINDUSTRY | 7 | Aug 19, 2026 | clinicaltrials |
| NCT07774611 | An Open-label Study of SG1827 Combined With Anti-PD-1/PD-L1 Antibody and Bevacizumab in Patients With Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 180 | Hangzhou Sumgen Biotech Co., Ltd.INDUSTRY | 1 | Aug 19, 2026 | clinicaltrials |
| NCT02210078 | Donor Cytomegalovirus-Specific Cytotoxic T-Lymphocytes in Treating Patients With a Persistent Cytomegalovirus Infection | active not recruiting | Phase 2 | 49 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT05919264 | FOG-001 in Locally Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 619 | Parabilis Medicines, Inc.INDUSTRY | 2 | Aug 17, 2026 | clinicaltrials |
| NCT06616766 | A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946 | recruiting | Phase 1 / Phase 2 | 201 | Yuhan CorporationINDUSTRY | 2 | Aug 17, 2026 | clinicaltrials |
| NCT06635785 | Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors(BiPAVE-001) | recruiting | Phase 1 / Phase 2 | 387 | OncoC4, Inc.INDUSTRY | 1 | Aug 17, 2026 | clinicaltrials |
| NCT07440290 | DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT07767474 | A Study to Evaluate ATX-898 in Participants With Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 343 | Antares Therapeutics, IncINDUSTRY | 0 | Aug 17, 2026 | clinicaltrials |
| NCT07769242 | Phase I/II Clinical Trials of SHR-8203 Injection in Participants With Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 200 | Beijing Suncadia Pharmaceuticals Co., LtdINDUSTRY | 1 | Aug 17, 2026 | clinicaltrials |
| NCT03742895 | Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002) | active not recruiting | Phase 2 | 329 | Merck Sharp & Dohme LLCINDUSTRY | 21 | Aug 14, 2026 | clinicaltrials |
| NCT06425926 | Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 117 | Georgiamune IncINDUSTRY | 1 | Aug 14, 2026 | clinicaltrials |
| NCT07661459 | Optimizing Ancillary Therapies With Immune Checkpoint Inhibitors for Solid Tumors (OAT ICI)(OAT ICI) | recruiting | Phase 2 | 98 | Val AdamsOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT05009329 | A Study of JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation in China | active not recruiting | Phase 1 / Phase 2 | 315 | Allist Pharmaceuticals, Inc.INDUSTRY | 1 | Aug 13, 2026 | clinicaltrials |
| NCT05722288 | Time-Restricted Eating Versus Nutritional Counseling for the Reduction of Radiation or Chemoradiation Tx Side Effects in Patients With Prostate, Cervical, or Rectal Cancers | active not recruiting | Phase 2 | 49 | City of Hope Medical CenterOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT07266428 | A Study of OTP-01, a Dual Paratopic PD-1/VEGFR2 Antibody, in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 170 | Ottimo Pharma LimitedINDUSTRY | 8 | Aug 13, 2026 | clinicaltrials |
| NCT05272709 | TT-702 in Patients With Advanced Solid Tumours.(CURATE) | recruiting | Phase 1 / Phase 2 | 60 | Cancer Research UKOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT06526819 | SMP-3124LP in Adults With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 120 | Sumitomo Pharma America, Inc.INDUSTRY | 2 | Aug 12, 2026 | clinicaltrials |
| NCT06827054 | Psilocybin With Psychotherapy for Improving Chronic Pain in Cancer Patients Requiring Opioids | not yet recruiting | Phase 2 | 20 | Roswell Park Cancer InstituteOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT07229612 | A Phase I/II Clinical Study of SHR-4298 Injection in Patients With Malignant Solid Tumors | recruiting | Phase 1 / Phase 2 | 200 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Aug 12, 2026 | clinicaltrials |
| NCT01989585 | Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma | active not recruiting | Phase 1 / Phase 2 | 75 | National Cancer Institute (NCI)NIH | 1 | Aug 11, 2026 | clinicaltrials |
| NCT03927885 | Open Labeled Placebo in Reducing Cancer Related Fatigue in Patients With Advanced Cancer | active not recruiting | Phase 2 / Phase 3 | 100 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT05592626 | A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors(START-001) | recruiting | Phase 1 / Phase 2 | 366 | Marengo Therapeutics, Inc.INDUSTRY | 4 | Aug 11, 2026 | clinicaltrials |
| NCT07160725 | A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 540 | Bristol-Myers SquibbINDUSTRY | 5 | Aug 11, 2026 | clinicaltrials |
| NCT06237881 | A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 15 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT06577194 | Neoadjuvant Short-Course Radiotherapy Followed by CAPOX Plus PD-1 Antibody and IL-2 in Locally Advanced Rectal Cancer (PRIDE01) | active not recruiting | Phase 2 | 35 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07098988 | Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC | recruiting | Phase 2 | 107 | CatalYm GmbHINDUSTRY | 7 | Aug 10, 2026 | clinicaltrials |
| NCT04280081 | A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation(LIBRETTO-321) | active not recruiting | Phase 2 | 77 | Eli Lilly and CompanyINDUSTRY | 1 | Aug 7, 2026 | clinicaltrials |
| NCT05944224 | A Study to Efficacy and Safety of SPH4336 Monotherapy or in Combination With Cadonilimab in Patients With Advanced Solid Tumors. | recruiting | Phase 1 / Phase 2 | 63 | Shanghai Pharmaceuticals Holding Co., LtdINDUSTRY | 1 | Aug 6, 2026 | clinicaltrials |
| NCT07749586 | A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 499 | Arvinas Inc.INDUSTRY | 1 | Aug 6, 2026 | clinicaltrials |
| NCT07751042 | Phase 1/2 Study of Intravenous Injection of STX-003 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab | recruiting | Phase 1 / Phase 2 | 220 | Strand Therapeutics Inc.INDUSTRY | 1 | Aug 6, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Aug 25, 2026source: clinicaltrials